 This study was originally planned as a 48-week, Phase 3, randomized, open-label, multicenter study comparing EFVFTCTDF administered as the individual component drugs versus CBV lamivudinezidovudine EFV to assess the efficacy and safety of both treatments in ART-Naive, HIV-1 infected participants. The regimen of CBV administered twice daily EFV administered once daily served as the active control treatment and was compared with the regimen of EFVFTCTDF; each component drug in the EFVFTCTDF regimen was administered once daily. 